

FORM 8

NOTICE OF PROPOSED PROSPECTUS OFFERING

Please complete the following:

Name of Listed Issuer: Emerald Health Therapeutics, Inc. (the "Issuer").

Trading Symbol: EMH

Date: August 5, 2021

Is this an updating or amending Notice: Yes No

If yes provide date(s) of prior Notices: _____.

Issued and Outstanding Securities of Issuer Prior to Proposed Prospectus Offering:
213,322,095

Date of News Release Announcing Proposed Prospectus Offering: The issuer will issue a news release on the signing of the equity distribution agreement and filing of the prospectus supplement to its base shelf prospectus dated June 21, 2021 expected to be on or around August 10, 2021.

(or provide explanation if news release not disseminated yet and expected date or circumstances that are expected to trigger news release dissemination)

1. Prospectus Offering

1. Description of securities to be issued:

- (a) Class: Common Shares
- (b) Number: to be determined in the context of the market
- (c) Price per security: to be determined in the context of the market
- (d) Voting rights: one vote per common share

2. Provide details of the net proceeds to the Issuer as follows:

- (a) Per security: to be determined in the context of the market.
- (b) Aggregate proceeds: up to \$20,000,000

3. Provide description of any Warrants (or options) including: Not applicable
 - (a) Number _____ .
 - (b) Number of securities eligible to be purchased on exercise of Warrants (or options) _____ .
 - (c) Exercise price _____ .
 - (d) Expiry date _____ .
 - (e) Other significant terms _____ .

4. Provide the following information if debt securities are to be issued: Not applicable
 - (a) Aggregate principal amount _____ .
 - (b) Maturity date _____ .
 - (c) Interest rate _____ .
 - (d) Conversion terms _____ .
 - (e) Default provisions _____ .

5. Details of currently issued and outstanding shares of each class of shares of the Issuer: _____

 _____ .

6. Describe any unusual particulars of the offering (i.e. tax “flow through” shares, special warrants, etc.).
 _____ .

7. Provide details of the use of the proceeds: For general corporate purposes including funding ongoing operations and/or working capital requirements, to repay indebtedness, if any, outstanding from time to time, and to fund capital projects and potential future acquisitions .

8. Provide particulars of any proceeds of the offering which are to be paid to Related Persons of the Issuer: None
9. Provide details of the amounts and sources of any other funds that will be available to the Issuer prior to or concurrently with the completion of the offering: None.
10. Provide the following information for any agent's fee, commission, bonus or finder's fee, or other compensation paid or to be paid in connection with the offering (including warrants, options, etc.):
- (a) Details of any dealer, agent, broker, finder or other person receiving compensation in connection with the offering (name, address, beneficial ownership where applicable):
 - (b) Cash: 3% of the gross proceeds from the sales of Offered Shares made under the Equity Distribution Agreement . .
 - (c) Securities _____ .
 - (d) Other _____ .
 - (e) Expiry date of any options, warrants etc. _____ .
 - (f) Exercise price of any options, warrants etc. _____ .
11. State whether the sales agent, broker, dealer, finder, or other person receiving compensation in connection with the offering is a Related Person of the Issuer with details of the relationship: Not applicable.
12. Provide details of the manner in which the securities being offered are to be distributed. Include details of agency agreements and sub-agency agreements outstanding or proposed to be made including any assignments or proposed assignments of any such agreements and any rights of first refusal on future offerings: Issued pursuant to an equity distribution agreement through an at-the-market offering.
13. Attach any term sheet, engagement letter or other document setting out terms, conditions or features of the proposed offering. See attached equity distribution agreement.


Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance on behalf of the Issuer.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 8 Notice of Proposed Prospectus Offering is true.

Dated August 5, 2021.

Jennifer Hepburn
Name of Director or Senior
Officer


Signature

Chief Financial Officer
Official Capacity